IMARC Group, a leading market research company, has recently releases report titled “Dengue Testing Market Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global dengue testing market size, share, growth, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Dengue testing is utilized to diagnose dengue fever, which is a virus spread by mosquitoes. It is primarily available in two types, including molecular tests like polymerase chain reaction (PCR) and serological tests like enzyme-linked immunosorbent assay (ELISA) identify antibodies generated in response to the infection. It facilitates early detection, allowing for prompt medical attention and lowering the possibility of consequences like dengue hemorrhagic fever. It offers a precise diagnosis that avoids mishandling, such as giving medications for a viral infection when they are not needed. It contributes to the larger goal of disease management and eradication by being a useful tool for epidemiological research and vaccine development.

The global dengue testing market size reached US$ 555.5 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 761.6 Million by 2028, exhibiting a growth rate (CAGR) of 5.2% during 2023-2028.

Request Sample Copy of This Report: https://www.imarcgroup.com/dengue-testing-market/requestsample

What are the growth prospects and trends in the dengue testing industry?

At present, the rising occurrence of dengue cases around the world due to lack of effective vector control represents one of the crucial factors impelling the market growth. Additionally, increasing advancements in diagnostic technologies, such as the development of rapid testing kits and point-of-care tests (POCT), are facilitating quicker and more accurate diagnoses.

Besides this, the growing efforts to educate the public about the seriousness of dengue fever are offering a favorable market outlook. In addition, the increasing collaboration between public and private entities for research and development (R&D) of better testing methods is supporting the market growth. Furthermore, the growing focus on combating vector-borne diseases, including dengue, by international bodies like the World Health Organization (WHO) is positively influencing the market. Apart from this, rising improvements in supply chain management are ensuring the easy availability of diagnostic kits and tools.

Additionally, the increasing integration of data analytics in healthcare to predict dengue outbreaks is contributing to the market growth. Moreover, the growing availability of medical supplies, including test kits, through online platforms is making it easier for healthcare providers to procure them.

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Test Type:

  • ELISA-based Tests
  • RT-PCR based Tests
  • Dengue IgG/IgM Rapid Test
  • Others

Breakup by End User:

  • Hospitals
  • Diagnostic Centers
  • Others

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163